These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9869575)

  • 1. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
    Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
    Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
    Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.
    Arthur M; Depardieu F; Reynolds P; Courvalin P
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1875-80. PubMed ID: 10428906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis.
    Lafaurie M; Perichon B; Lefort A; Carbon C; Courvalin P; Fantin B
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2826-30. PubMed ID: 11557476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis.
    Aslangul E; Baptista M; Fantin B; Depardieu F; Arthur M; Courvalin P; Carbon C
    J Infect Dis; 1997 Mar; 175(3):598-605. PubMed ID: 9041331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP; Andrews J; Wise R
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
    Al-Nawas B; Swantes J; Shah PM
    Infection; 2000; 28(4):214-8. PubMed ID: 10961526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1998 Apr; 42(4):981-3. PubMed ID: 9559828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.
    Nicolau DP; Marangos MN; Nightingale CH; Patel KB; Cooper BW; Quintiliani R; Courvalin P; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):55-60. PubMed ID: 8787879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
    Kirk M; Hill RL; Casewell MW; Beighton D
    Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
    [No Abstract]   [Full Text] [Related]  

  • 15. Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis.
    Lefort A; Baptista M; Fantin B; Depardieu F; Arthur M; Carbon C; Courvalin P
    Antimicrob Agents Chemother; 1999 Mar; 43(3):476-82. PubMed ID: 10049254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
    Jones RN; Barrett MS; Erwin ME
    Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.
    Lefort A; Lafaurie M; Massias L; Petegnief Y; Saleh-Mghir A; Muller-Serieys C; Le Guludec D; Fantin B
    Antimicrob Agents Chemother; 2003 Jan; 47(1):216-22. PubMed ID: 12499194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.